Evidence map›Paper›PMID 40943199›Full record

ReviewInternational journal of molecular sciences2025

A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome.

Alexandros Giannakis, Eugenia Kloufetou, Louisa Pechlivani, Chrissa Sioka, George Alexiou, Spiridon Konitsiotis, Athanassios P Kyritsis

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexandros GiannakisDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0002-7787-9979
Eugenia KloufetouDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece.
Louisa PechlivaniNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0002-3003-9497
Chrissa SiokaNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0002-2184-4945
George AlexiouNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-0257-4481
Spiridon KonitsiotisDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0002-5217-1317
Athanassios P KyritsisDepartment of Neurology, Faculty of Medicine, School of Health Sciences, University Campus, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-0370-1024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although diagnostic criteria and research are constantly advancing, distinguishing between progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) remains a significant challenge. This difficulty stems from their similar clinical symptoms and the lack of reliable biomarkers. In this work, we present a detailed review of fluorodeoxyglucose (FDG)-positron emission tomography (PET), exploring its potential role in differentiating PSP and CBS, drawing on their established utility in other neurodegenerative diseases. We searched the PubMed database from its inception for original research articles assessing the utility of FDG-PET for the diagnosis or differential diagnosis of PSP and CBS from other neurodegenerative conditions. A total of 91 studies were eligible. These 91 studies were categorized as follows: (a) 20 studies included only patients with PSP, (b) 15 studies included only patients with CBS, (c) 39 studies involved patients with Parkinson's disease and atypical Parkinsonian disorders, including subgroups of PSP and/or CBS, and (d) 17 studies compared patients with PSP and/or CBS to individuals with Alzheimer's disease, frontotemporal dementia, or other dementias. Most FDG-PET studies involving PSP and CBS were not specifically designed for these disorders. An additional obstacle lies in the methodological variability across studies. Despite several studies achieving high diagnostic accuracy for PSP and/or CBS with specificity exceeding 90% using FDG-PET, sensitivity remains considerably lower. CBS appears to have a distinct hypometabolic pattern compared to PSP, marked by asymmetry and predominant cortical involvement. CBS more often affects posterior cortical regions (parietal and posterior parts of the frontal cortex, and sometimes temporal and occipital parts) and the thalamus, whereas PSP appears to affect the striatum, frontal cortex, anterior cingulate, and subtentorial structures, typically in a more symmetrical manner. Large, multicenter studies are needed, utilizing standardized imaging and protocols.

Indexed as

Corticobasal DegenerationFluorodeoxyglucose F18Positron-Emission TomographySupranuclear Palsy, ProgressiveBrainDiagnosis, DifferentialHumansParkinson DiseaseFluorodeoxyglucose F18biomarkercorticobasal syndromedifferential diagnosispositron emission tomographyprogressive supranuclear palsy

Identifiers

PMID40943199
PMCPMC12428065

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.